Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis
Shintaro Sakurai, Teruo Jojima, Toshie Iijima, Takuya Tomaru, Isao Usui, Yoshimasa Aso
Topics & Concepts
EmpagliflozinInternal medicineMedicineFibrinolysisEndocrinologyPlasminogen activator inhibitor-1AdiponectinType 2 diabetesDiabetes mellitusPlasminogen activatorInsulin resistanceAdipokines, Inflammation, and Metabolic DiseasesBlood properties and coagulationDiabetes Treatment and Management